Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
10
×
boston blog main
10
×
boston top stories
genentech
10
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
new york blog main
indiana blog main
indiana top stories
new york top stories
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
cancer
deals
detroit blog main
detroit top stories
eli lilly
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
bristol-myers squibb
celgene
fda
pfizer
roche
clinical trials
ipo
startups
boston
What
bio
drug
roundup
cancer
fda
medicines
news
approval
approved
big
biotech
blueprint
companies
drugs
latest
liver
medical
pharmaceutical
regulatory
ret
roche
today
acquire
address
adu
agreed
aiming
alzheimer’s
ambys
annual
appetite
approves
august
beats
bids
billion
biogen
black
bread
breast
Language
unset
Current search:
genentech
×
biotech
×
" boston blog main "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine